Pranikoff T, Hirschl R B, Steimle C N, Anderson H L, Bartlett R H
Department of Surgery, University of Michigan Medical School, Ann Arbor, USA.
ASAIO J. 1994 Jul-Sep;40(3):M339-43. doi: 10.1097/00002480-199407000-00020.
The efficacy of extracorporeal life support (ECLS, ECMO) in the management of severe adult cardiorespiratory failure remains controversial. The purpose of this review is to evaluate the authors' institutional experience with ECLS in adult patients. Between 1988 and 1993, 65 moribund patients with respiratory (n = 51) and cardiac (n = 14) failure were supported with ECLS. Criteria for initiation of ECLS were: 90% chance of mortality despite maximal conventional respiratory management, good potential for recovery, and age younger than 60 years. Venovenous bypass was used in 40 and venoarterial in 25 patients. Respiratory management included low rate, low pressure ventilation with an inspired oxygen fraction < or = 0.5 and tracheostomy tube placement. Continuous systemic heparinization was used, maintaining whole blood activated clotting time (ACT) between 180 and 200 sec. Survival data are summarized as follows: pneumonia (n = 25) 56%, adult respiratory distress syndrome (n = 24) 58%, airway support (n = 2) 100%, and cardiac support (n = 14) 29%. The most common complication was bleeding (68%), which was managed in most patients by reduction of anticoagulation or local measures such as packing. Data from survivors and nonsurvivors of ECLS in patients with respiratory failure were compared in an attempt to define prognostic indicators of improved survival. The only prognostic indicator of survival that could be identified was the period of time on the ventilator before the initiation of ECLS (survivors = 3.0 +/- 2.4 days, nonsurvivors = 6.1 +/9- 4.0 days, P < 0.005). It is concluded that ECLS can be a life saving modality for the management of severe adult cardiorespiratory failure. Earlier institution of ECLS in the course of cardiopulmonary failure may improve outcome.
体外生命支持(ECLS,即体外膜肺氧合,ECMO)在治疗成人严重心肺功能衰竭中的疗效仍存在争议。本综述的目的是评估作者所在机构在成人患者中应用ECLS的经验。1988年至1993年间,65例患有呼吸衰竭(n = 51)和心力衰竭(n = 14)的濒死患者接受了ECLS支持。启动ECLS的标准为:尽管进行了最大程度的传统呼吸管理,死亡几率仍达90%,恢复潜力良好,且年龄小于60岁。40例患者采用静脉 - 静脉旁路,25例采用静脉 - 动脉旁路。呼吸管理包括低频率、低压力通气,吸入氧分数≤0.5,并放置气管造口管。采用持续全身肝素化,使全血活化凝血时间(ACT)维持在180至200秒之间。生存数据总结如下:肺炎(n = 25)患者生存率为56%,成人呼吸窘迫综合征(n = 24)患者生存率为58%,气道支持(n = 2)患者生存率为100%,心脏支持(n = 14)患者生存率为29%。最常见的并发症是出血(68%),大多数患者通过减少抗凝或采取局部措施(如填塞)进行处理。对呼吸衰竭患者中ECLS幸存者和非幸存者的数据进行比较,试图确定改善生存的预后指标。唯一可确定的生存预后指标是启动ECLS前使用呼吸机的时间(幸存者 = 3.0±2.4天,非幸存者 = 6.1±4.0天,P < 0.005)。结论是,ECLS可作为治疗成人严重心肺功能衰竭的一种挽救生命的方式。在心肺功能衰竭过程中更早地应用ECLS可能会改善预后。